NCT06450418|Recruiting
Loading search results
Sponsor study identifier
observational
150
1 country
1
Study Start
July 12, 2024
Actual (reported)Primary Completion
January 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Many people living with neurodegenerative conditions like dementia, motor neuron disease (MND), multiple sclerosis (MS), and Parkinson's disease (PD), suffer from speech problems. Using common digital technologies such as smartphone apps, the investigators can record and analyse speech in detail to provide new information for people living with these conditions, researchers, and healthcare professionals. This study will investigate the use of these digital speech recordings to help diagnose and monitor these conditions. To take part, participants will have either a diagnosis of dementia, motor neuron disease, Parkinson's disease or Multiple Sclerosis, OR they will have no diagnosis of a neurological condition. Researchers will compare people with a diagnosis of a Neurological condition to those without.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 9, 2024
Actual (reported)June 10, 2024
Actual (reported)July 12, 2024
Actual (reported)January 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary outcome measures
Area under the curve (AUC) of the receiver operating characteristic (ROC) curve for each of the 4 binary classifiers distinguishing between a disease-positive group and a healthy control group.
24 months
Secondary outcome measure
24 months
Secondary outcome measure
24 months
Participants with Neurodegenerative Disorders and their relatives or carers without a diagnosis of a Neurodegenerative disorder.
NHS Lothian
Edinburgh, United Kingdom
Tam J, Weaver C, Ihenacho A, Newton J, Virgo B, Barrett S, Neale J, Perry D, Smith A, Chandran S, Watts O, Pal S; DASH Consortium. Digital App for Speech and Health Monitoring Study (DASH): protocol for a prospective longitudinal case-control observational study for developing speech datasets in neurodegenerative disorders and dementia. BMJ Open. 2025 Dec 5;15(12):e100222. doi: 10.1136/bmjopen-2025-100222.
Participants can additionally and optionally consent for blood samples to be obtained during the study. These samples will be collected and stored with the intention of exploring emerging blood-based biomarkers.
Suvankar Pal, Prof
University of Edinburgh
First Submitted
February 9, 2024
First Posted
June 10, 2024
Study Start
July 12, 2024
Actual (reported)Primary Completion
January 30, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
Contact the study team to confirm eligibility.
Study Completion
June 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 10, 2026
Record last verified: 2026-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: